Literature DB >> 350902

Inherited deficiency of the seventh component of complement associated with nephritis. Propensity to formation of C56 and related C7-consuming activity.

G R Nemerow, H Gewurz, S G Osofsky, T F Lint.   

Abstract

A 46-yr-old female with chronic pyelonephritis was found to lack complement (C) activity by the use of hemolytic screen assays in agarose gels. These assays also revealed a propensity of patient serum to form an activated complex of the fifth and sixth components of C, C56. Each of the C component hemolytic activities was present in normal or elevated amounts with the exception of C7, which was undetectable; addition of purified C7 led to the restoration of hemolytic activity. C-dependent phagocytosis, immune adherence, and neutrophil chemotaxis were normal. Family studies demonstrated that the defect was transmitted as an autosomal codominant apparently not linked with alleles at the HLA-A or HLA-B loci. Persisting C56 was readily formed in this as compared to normal serum upon incubation with multiple C activators including zymosan, inulin, immune complexes, heat-aggregated human gamma globulin, endotoxin, and agarose. A heat-stable (56 degrees C, 30 min) activity which consumed C7 with time-and temperature-dependent kinetics was detected in plasma and serum, and seemed to be similar to a "C7 inactivator" previously described in another C7-deficient individual. However, this activity was found to have properties identical to those of C56 during low ionic strength precipitation and chromatography on Sephadex G-200, to be specifically removed upon passage through an anti-C5 immunoadsorbent column, and to be associated with a small amount of C56, suggesting that it represents an expression of small amounts of C56 rather than a new C-inhibitory activity. Thus, an individual with chronic nephritis lacking C7 is reported; the utility of a hemolytic screen assay in agarose plates for the detection of such patients is emphasized; persisting C56 is shown readily to be formed in this serum; and the presence of C7-consuming activity which is associated with and in all likelihood attributable to C56 is shown.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 350902      PMCID: PMC372686          DOI: 10.1172/JCI109080

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  Binding of the complement intermediate C56 to zymosan in acute phase human sera.

Authors:  P J Baker; L G Rubin; T F Lint; B C McLeod; H Gewurz
Journal:  Clin Exp Immunol       Date:  1975-04       Impact factor: 4.330

2.  Measurements of complement by agglutination of human erythrocytes reacting in immune-adherence.

Authors:  K NISHIOKA
Journal:  J Immunol       Date:  1963-01       Impact factor: 5.422

3.  Homozygous C2 deficiency with fulminant lupus erythematosus: severe nephritis via the alternative complement pathway.

Authors:  A Gewurz; T F Lint; J L Roberts; H Zeitz; H Gewurz
Journal:  Arthritis Rheum       Date:  1978 Jan-Feb

4.  Homozygous deficiency of C3 in a patient with repeated infections.

Authors:  C A Alper; H R Colten; F S Rosen; A R Rabson; G M Macnab; J S Gear
Journal:  Lancet       Date:  1972-12-02       Impact factor: 79.321

5.  Reactive haemolysis--a distinctive form of red cell lysis.

Authors:  R A Thompson; D S Rowe
Journal:  Immunology       Date:  1968-05       Impact factor: 7.397

6.  Hereditary deficiency of the sixth component of complement in man. I. Immunochemical, biologic, and family studies.

Authors:  J P Leddy; M M Frank; T Gaither; J Baum; M R Klemperer
Journal:  J Clin Invest       Date:  1974-02       Impact factor: 14.808

7.  C567-initiated cytolysis of lymphoid cells: description of the phenomenon and studies on its control by C567 inhibitors.

Authors:  P J Baker; T F Lint; R F Mortensen; H Gewurz
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

8.  Hereditary C7 deficiency. Diagnosis and HLA studies in a French-Canadian family.

Authors:  J M Delâge; P Bergeron; J Simard; G Lehner-Netsch; E Prochazka
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

9.  A second case of human C3b inhibitor (KAF) deficiency.

Authors:  R A Thompson; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1977-01       Impact factor: 4.330

10.  Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9.

Authors:  P J Lachmann; R A Thompson
Journal:  J Exp Med       Date:  1970-04-01       Impact factor: 14.307

View more
  5 in total

1.  Efficacy of HIV-specific and 'antibody-independent' mechanisms for complement activation by HIV-infected cells.

Authors:  M N Saarloos; T F Lint; G T Spear
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

2.  Combined total deficiency of C7 and C4B with systemic lupus erythematosus (SLE).

Authors:  O G Segurado; A A Arnaiz-Villena; P Iglesias-Casarrubios; J Martinez-Laso; J L Vicario; G Fontan; M Lopez-Trascasa
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

3.  Inherited deficiency of C8 in a patient with recurrent meningococcal infections: further evidence for a dysfunctional C8 molecule and nonlinkage to the HLA system.

Authors:  P Densen; E J Brown; G J O'Neill; F Tedesco; R A Clark; M M Frank; D Webb; J Myers
Journal:  J Clin Immunol       Date:  1983-01       Impact factor: 8.317

4.  Paradoxical reconstitution of complement activity following plasma transfusion of an individual with deficiency of the seventh component of complement.

Authors:  A E Platonov; R Würzner; B Beloborodov; A M Jones; D V Troshansky; I V Vershinina; P J Lachmann; A Orren
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

5.  Familial deficiency of the seventh component of complement associated with recurrent meningococcal infections.

Authors:  W Nürnberger; H Pietsch; R Seger; T Bufon; V Wahn
Journal:  Eur J Pediatr       Date:  1989-08       Impact factor: 3.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.